IFRX · InflaRx NV
United States · RS rating 44 · As of 2026-10-14
| Price | 1.48 USD |
|---|---|
| 1-day change | -4.5% |
| RS rating (overall / 1M / 3M / 12M) | 44 / 8 / 17 / 72 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 37 / 33 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -12.5% |
| Sales growth Q/Q | -242.4% |
| Distance from 52-week high | +46.0% |
| Market cap (USD) | $112.8M |